Regeneron Pharmaceuticals Inc.

01/25/2022 | Press release | Distributed by Public on 01/24/2022 18:00

U.S. Food and Drug Administration Revises Emergency Use Authorization for REGEN-COV® (casirivimab and imdevimab) Antibody Cocktail due to Omicron Variant